Insulin Delivery Devices Market Poised for Steady Growth, Fueled by Innovation and Rising Surgical Volumes | DelveInsight

The global insulin delivery devices market was valued at USD 15.51 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.28% from 2024 to 2030, reaching USD 26.35 billion by 2030. The increasing demand for insulin delivery devices is mainly driven by the rising prevalence of diabetes, influenced by lifestyle changes, aging populations, and genetic factors. Additionally, awareness campaigns and educational efforts have greatly enhanced public understanding of diabetes management. Both patients and healthcare providers are now more knowledgeable about the advantages of advanced insulin delivery devices, which provide precise dosing, ease of use, and better blood glucose control compared to traditional methods. Furthermore, technological innovations, such as smart insulin pumps, integration with continuous glucose monitors (CGM), and mobile app connectivity, have further propelled market growth. Together, these factors contribute to a strong market landscape, driving demand for insulin delivery devices and supporting improved health outcomes for diabetes patients throughout the forecast period from 2024 to 2030.

DelveInsight's Insulin Delivery Devices Market Insights report provides the current and forecast market analysis, individual leading Insulin Delivery Devices companies' market shares, challenges, Insulin Delivery Devices market drivers, barriers, and trends, and key Insulin Delivery Devices companies in the market.

Request for a detailed sample report @ https://www.delveinsight.com/report-store/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Insulin Delivery Devices Market Report
The Insulin Delivery Devices market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Insulin Delivery Devices market during the forecast period.
Notable Insulin Delivery Devices companies such as Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and several others are currently operating in the Insulin Delivery Devices market.
In April 2025, Medtronic announced that the FDA approved the Simplera SyncTM sensor, enhancing its MiniMedTM 780G system by offering users greater flexibility. This approval enables users to select between the GuardianTM 4 sensor and the Simplera SyncTM sensor, both compatible with the system's advanced Meal DetectionTM technology.
On September 3, 2024, Embecta Corp. revealed that the FDA granted 510(k) clearance for its new disposable insulin delivery system. Designed for adults with type 1 (T1D) and type 2 diabetes (T2D), this system features a tubeless patch pump with a 300-unit insulin reservoir. Its development incorporated feedback from patients and healthcare professionals to enhance diabetes management.
In November 2023, Terumo Corporation introduced an insulin syringe in India aimed at patients requiring regular insulin injections to manage their diabetes.
In November 2022, Medtronic launched the world's first and only infusion set for insulin pumps in the U.S. that doubles the wear time to up to 7 days.


To read more about the latest highlights related to the Insulin Delivery Devices market, get a snapshot of the key highlights entailed in the Global Insulin Delivery Devices Market Report https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Insulin Delivery Devices Overview

Insulin delivery devices are medical tools designed to administer insulin to individuals with diabetes, helping to regulate blood glucose levels and manage the condition effectively.

Insulin Delivery Devices Market Insights

North America is projected to hold the largest share of the insulin delivery devices market in 2023 compared to other regions. This growth is primarily driven by the rising prevalence of diabetes across the area. Moreover, the region benefits from the presence of numerous key market players engaged in activities such as reimbursement, mergers, acquisitions, and strategic partnerships, which are expected to further accelerate market expansion. Increased awareness campaigns, along with new product approvals and launches, are also contributing to the growth of the insulin delivery devices market in North America.

According to the latest data from the Centers for Disease Control and Prevention (CDC), an estimated 38.4 million people of all ages-equivalent to 11.6% of the U.S. population-had diabetes in 2021. Additionally, among adults aged 18 and older, 38.1 million individuals, or 14.7% of the adult population, were affected by diabetes in the same year.


To know more about why North America is leading the market growth in the Insulin Delivery Devices market, get a snapshot of the Insulin Delivery Devices Market Outlook https://www.delveinsight.com/report-store/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Insulin Delivery Devices Market Dynamics

Furthermore, the International Diabetes Federation's recent update states that in 2021, around 537 million adults aged 20 to 79 were living with diabetes. This figure is expected to increase to 643 million by 2030 and reach 783 million by 2045. The same report highlights that in 2021, approximately 21.1 million live births worldwide (16.7%) were affected by hyperglycemia during pregnancy. Women over the age of 45 or those with a history of gestational diabetes are at an increased risk of developing type 2 diabetes after childbirth.

Additionally, according to the IDF Diabetes Atlas 2022 data, of the 8.75 million individuals living with Type 1 Diabetes globally, 1.52 million were under the age of 20. Interestingly, 62% of new Type 1 diabetes cases in 2022 were diagnosed in people aged 20 or older. This wide age distribution emphasizes the need for adaptable insulin delivery devices suitable for both younger and older patients to effectively manage their insulin. The rising number of young patients calls for devices that are easy to use, discreet, and compatible with active lifestyles-such as patch pumps and smart insulin pens-thereby driving growth in the insulin delivery devices market.

Insulin Delivery Devices Market Drivers:
Rising incidence of diabetes
Increasing patient preference for non-invasive and convenient delivery
Increase in product approval and launches across the globe

Get a sneak peek at the Insulin Delivery Devices market dynamics @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Scope of the Insulin Delivery Devices Market Report:
Coverage: Global
Study Period: 2022 to 2032
Key Insulin Delivery Devices Companies: Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

Which MedTech key players in the Insulin Delivery Devices market are set to emerge as the trendsetter, explore @ Insulin Delivery Devices Companies https://www.delveinsight.com/report-store/insulin-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:

Kritika Rehani
Assistant Manager, Digital Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.